Drug Trial Radar · NCT06998056
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jun 9, 2025
Primary completion
Dec 4, 2025
Study completion Dec 4, 2025
Sponsor
- Lead sponsor
- Arcutis Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 months, up to 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Conditions
- Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.05%Drug
ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject incidence of adverse eventsTime frame: 4 weeks
- Subject incidence of serious adverse eventsTime frame: 4 weeks
- Incidence of application site reactionsTime frame: 4 weeks
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
Arcutis Clinical Study Site 208
Birmingham, Alabama
Arcutis Clinical Study Site 221
Bryant, Arkansas
Arcutis Clinical Study Site 214
Fountain Valley, California
Arcutis Clinical Study Site 209
Rancho Santa Margarita, California
Arcutis Clinical Study Site 207
Coral Gables, Florida
Arcutis Clinical Study Site 217
Delray Beach, Florida
Arcutis Clinical Study Site 213
Jacksonville, Florida
Arcutis Clinical Study Site 223
Boise, Idaho
Arcutis Clinical Study Site 219
West Lafayette, Indiana
Arcutis Clinical Study Site 212
Minneapolis, Minnesota
Arcutis Clinical Study Site 211
Portsmouth, New Hampshire
Arcutis Clinical Study Site 220
Mason, Ohio
Arcutis Clinical Study Site 206
Portland, Oregon
Arcutis Clinical Study Site 222
Summerville, South Carolina
Arcutis Clinical Study Site 210
Bellaire, Texas
Arcutis Clinical Study Site 224
Fort Worth, Texas
Arcutis Clinical Study Site 202
San Antonio, Texas
Arcutis Clinical Study Site 203
Winnipeg, Manitoba, Canada
Arcutis Clinical Study Site 204
Halifax, Nova Scotia, Canada
Arcutis Clinical Study Site 216
Waterloo, Ontario, Canada
Arcutis Clinical Study Site 225
Saskatoon, Saskatchewan, Canada
Arcutis Clinical Study Site 201
Santo Domingo, Dominican Republic
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.